MRK vs NBTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
NBTX exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational instability. The valuation is extreme, with a Price/Sales ratio of 47.36 and a negative Price/Book ratio (-19.23), suggesting the company is trading on speculative future catalysts rather than current assets or earnings. While the stock has seen a massive 1-year price surge of 855.9% and maintains a 'strong_buy' analyst consensus, the deterministic data reveals a company with negative equity and unsustainable margins. The disconnect between the technical momentum and the underlying financial decay presents a high-risk profile.
Compare Another Pair
Related Comparisons
MRK vs NBTX: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Nanobiotix S.A. (NBTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.